Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01885195 · FLOW

Participant flow

MEK162 for Patients With RAS/RAF/MEK Activated Tumors · Source last updated 2021-02-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received an oral dose of 45 milligram (mg) of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.
    id
    FG000
    title
    Binimetinib (MEK162)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        29
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        67
      type
      Disease Progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Protocol Deviation
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    6. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Patient/guardian decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants diagnosed with select solid tumors or hematological malignancies pre-identified (prior to study consent) and had an activation of the v-raf murine sarcoma viral oncogene (RAF)/ RAS oncogene \[rat sarcoma viral oncogene homologue\] (RAS)/mitogen-activated erk kinase (MEK) pathway and whose disease had progressed on or after standard treatment.
Complete source fields
groups
  1. description
    Participants received an oral dose of 45 milligram (mg) of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.
    id
    FG000
    title
    Binimetinib (MEK162)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        29
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        67
      type
      Disease Progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Protocol Deviation
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    6. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Patient/guardian decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        110
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants diagnosed with select solid tumors or hematological malignancies pre-identified (prior to study consent) and had an activation of the v-raf murine sarcoma viral oncogene (RAF)/ RAS oncogene \[rat sarcoma viral oncogene homologue\] (RAS)/mitogen-activated erk kinase (MEK) pathway and whose disease had progressed on or after standard treatment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice